ARS Pharmaceuticals (SPRY) said Friday it has signed an agreement with allergy immunotherapy firm ALK-Abello to co-promote Neffy nasal spray to up to 9,000 pediatricians in the US.
Under the four-year deal, ARS will recognize all US revenue and will continue to have sole responsibility for all US commercialization activities, ARS said.
ARS said it expects its operating expense outlook for 2025 to rise by about $3 million per quarter starting in Q3 under the deal but said its 2025 cash flow won't be impacted.
The agreement follows a licensing deal between ARS and ALK-Abello, which provided ARS with $145 million upfront and gave ALK commercialization rights to Neffy in Canada, the UK, the EU and other countries outside the US, ARS said.
Shares of ARS Pharmaceuticals were 3.5% higher in recent trading.
Price: 14.55, Change: +0.39, Percent Change: +2.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.